Andrew Kyle Henderson Robertson, Caterina Fortunata Ramogida, Paul Schaffer and Valery Radchenko* Pages 1 - 17 ( 17 )
Background: The development of radiopharmaceuticals containing 225Ac for targeted alpha therapy is an active area of academic and commercial research worldwide. Objectives: Despite promising results from recent clinical trials, 225Ac-radiopharmaceutical development still faces significant challenges that must be overcome to realize the widespread clinical use of 225Ac. Some of these challenges include the limited availability of the isotope, the challenging chemistry required to isolate 225Ac from any co-produced isotopes, and the need for stable targeting systems with high radiolabeling yields. Results: Here we provide a review of available literature pertaining to these challenges in the 225Acradiopharmaceutical field and also provide insight into how performed and planned efforts at TRIUMF - Canada’s particle accelerator centre - aim to address these issues.
Actinium-225, targeted alpha therapy, isotope production, radiochemistry, radiolabeling, TRIUMF.
Life Sciences Division, TRIUMF, Vancouver BC, Life Sciences Division, TRIUMF, Vancouver BC, Life Sciences Division, TRIUMF, Vancouver BC, Life Sciences Division, TRIUMF, Vancouver BC